• Yao Peng, Jiayuan Zhang, Tian Lan, Shengyue Liu, Tao Ye, and Yongzhou Wang.
• The Affiliated TCM Hospital of Southwest Medical University, Luzhou, China.
• Medicine (Baltimore). 2022 Nov 25; 101 (47): e31885e31885.

BackgroundThreatened miscarriage (TM) is an important factor endangering the health of pregnant women. It not only affects women's physical and mental health, but also destroys family happiness. To treat this disease, it is necessary to find a treatment with better clinical efficacy and fewer side effects. The purpose of this systematic study was to evaluate the efficacy and safety of phloroglucinol (PHL) combined with progesterone in the treatment of TM before 20 weeks of pregnancy.MethodsElectronic databases (EMBASE, PubMed, Cochrane Central Register of Controlled Trials, Web of Science, Elsevier, China National Knowledge Infrastructure, Chongqing VIP, and WanFang Data) were searched from inception until September. 2022. Randomized controlled trials of PHL combined with progesterone in the treatment of TM before 20 weeks of gestation will be included, and all articles will be independently screened and collected by 2 reviewers. Revman 5.3.5 software will be used for meta-analysis. The specific process is described in the Cochrane Handbook for Systematic Reviews.ResultsThe efficacy and safety of PHL combined with progesterone for the treatment of threatened abortion were comprehensively evaluated in terms of efficacy, efficiency, time of symptom relief, length of hospital stay, and incidence of adverse events.ConclusionThis study provides reliable evidence for the clinical application of PHL combined with progesterone for the treatment of TM.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

13 keywords...

hide…